Non-invasive Brain Stimulation for Gait Improvement in Patients With Spinal Cord Injury (SCI)

March 13, 2016 updated by: Joan Vidal, Institut Guttmann

Non-invasive Brain Stimulation in SCI

to optimize the functional outcome in early phase of gait rehabilitation in subacute incomplete SCI patients using rTMS as an additional treatment to physical therapy (e.g. to gait training in Lokomat®). Using this add-on therapeutic strategy, we expected larger improvement of gait function than with physical therapy alone.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive and painless procedure to modulate cortical excitability of motor areas and induce changes over the descending corticospinal output. This modulation may be useful to promote active recovery of motor function and to obtain functional benefit from gait rehabilitation. Through the use of repetitive high-frequency rTMS, improvement has been reported in motor and sensory functions measured by American Spinal Cord Injury Association (ASIA) Impairment Scale (AIS), and time to complete a peg-board task in four chronic incomplete cervical SCI patients.

Physical therapy aims to improve function of both undamaged and also, as far as possible, damaged neuronal structures. However, 'reorganization' of neuronal circuits is the target of specific training approaches. Therefore, the challenge is to guide CNS plasticity in order to optimize the functional outcome for a given individual. Hypothesized was that high-frequency rTMS coupled with gait training can improve motor recovery in the lower extremities and locomotion in incomplete SCI patients to a greater degree than sham stimulation.

Study Type

Interventional

Enrollment (Actual)

31

Phase

  • Phase 3

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

inclusion criteria:

  1. had subacute motor incomplete SCI (AIS-C or D),
  2. candidate for gait rehabilitation with Lokomat® after cervical or thoracic SCI;
  3. stable medical treatment at least one week before and during the study;
  4. without limitation of passive range of movement in joints
  5. agreed to participate after signing a written informed consent form.

exclusion criteria:

  1. unstable clinical state
  2. severe spasticity (MAS>=3)
  3. disagreed to sign consent form

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: active (real) rTMS (ACTIVE GROUP)

The patients were randomly distributed in two study groups: real or sham rTMS group.

For real rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes.

For real (active) rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes
Other Names:
  • active group
  • active rTMS
  • real rTMS
Sham Comparator: sham rTMS (SHAM GROUP)
For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2).

Sham Comparator: sham rTMS (SHAM GROUP)

For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2).

Other Names:
  • sham group
  • placebo group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ten-meters walking test (10MWT=Time in seconds to walk 10 meters.)
Time Frame: Change from Baseline 10MWT at 4 and 8 weeks
Patients with or without orthesis were asked to walk at their fastest but most comfortable speed and step length and cadence assessed during the 10MWT (We added the number of steps taken in 10 m. Step length (meters)=distance (m) x 2 / number of stops (heel to heel of same foot). Cadence (steps/min.)=number of steps x 60 / time (seconds))
Change from Baseline 10MWT at 4 and 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Modified Ashworth Scale (MAS)
Time Frame: Change from Baseline MAS at 4 weeks
Tests resistance to passive movement about a joint with varying degrees of velocity at knees
Change from Baseline MAS at 4 weeks
--Total motor score from upper (UEMS) and lower extremities (LEMS)
Time Frame: Change from Baseline 1UEMS and LEMS at 4 and 8 weeks
Total motor score from upper (UEMS) (score 50points) and lower extremities (LEMS) (score 50points) obtained from the standardized AIS clinical exam (total score=100)
Change from Baseline 1UEMS and LEMS at 4 and 8 weeks
Walking Index for SCI (WISCI) II
Time Frame: Change from Baseline WISCI-II at 4 and 8 weeks
The ranking of severity of gait is based on the severity of the impairment and not on functional independence in the environment.
Change from Baseline WISCI-II at 4 and 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2010

Primary Completion (Actual)

June 1, 2015

Study Completion (Actual)

August 1, 2015

Study Registration Dates

First Submitted

March 9, 2016

First Submitted That Met QC Criteria

March 13, 2016

First Posted (Estimate)

March 17, 2016

Study Record Updates

Last Update Posted (Estimate)

March 17, 2016

Last Update Submitted That Met QC Criteria

March 13, 2016

Last Verified

February 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • PI10/00442

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Functional Improvement

Clinical Trials on rTMS

3
Subscribe